Submitted for Publication: April 14, 2011; final revision received June 1, 2011; accepted July 15, 2011.
Author Contributions: Dr Elliott had full access to all the data in the study, performed the statistical analysis, and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: In the past 12 months, Dr Elliott received consultancy fees from Cambridge Cognition and P1vital. Dr Deakin variously performed consultancy, speaking engagements, and research for Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Schering Plough, Janssen-Cilag, and Servier (all fees are paid to the University of Manchester to reimburse them for the time taken); he has share options in P1vital. Dr Anderson received an honorarium for speaking from Lundbeck and grant support from Servier and AstraZeneca.
Funding/Support: This study was supported by grant LSHM-CT-2004-503474 from the NewMood European Union Integrated Research Programme. Dr Thomas was supported by a Medical Research Council Studentship.
Role of the Sponsor: The sponsor provided peer review of the study design and funded the work but had no further role in the design or conduct of the study or in the preparation, review, or approval of the manuscript.
Additional Contributions: Diana Chase, PhD; Kathryn Lloyd-Williams, BSc; Ivan Koychev, PhD; and Christine Bowen, BSc (Hons), assisted with recruitment and data acquisition. Roland Zahn, MD, provided helpful comments on a draft of the manuscript. For all their assistance, we thank the staff of the Wellcome Trust Clinical Research Facility, Manchester, where this research was performed.